Short course of primaquine for vivax malaria cure
Part of Infections clinical trials.
This trial tests whether a shorter course of primaquine can effectively prevent relapses of vivax malaria. It aims to make treatment easier and safer for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have vivax malaria confirmed by a blood test
- You have normal G6PD enzyme activity (a blood test will check this)
- You have a fever or had a fever in the last 48 hours
- You are at least 5 years old and weigh 14 kg or more
- You live in the study area and can be followed for 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This trial tests a two-drug combination to safely and quickly clear all stages of P. vivax malaria from your body. You must have confirmed vivax malaria, be within a certain weight range, and agree to hospital stay and follow-up visits over 6 months.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
This trial tests how well the drug primaquine works for people with vivax malaria who have intermediate or low levels of an enzyme called G6PD. It aims to find safe and effective treatment options for this group.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.